WHO Expert Committee on Drug Dependence [meeting held in Geneva from 17 to 22 April 1989] :
WHO Expert Committee on Drug Dependence [meeting held in Geneva from 17 to 22 April 1989] : twenty-sixth report.
= Comité OMS d' experts de la pharmacodépendance [réuni à Genève du 17 au 22 avril 1989] : vingt-sixième rapport = Comité de Expertos de la OMS en Farmacodependencia [se reunió en Ginebra del 17 al 22 abril de 1989] : 26o informe
- Geneva : World Health Organization, 1989.
- 32 p.
- World Health Organization technical report series ; no. 787 .
Records the recommendations of a WHO expert committee responsible for reviewing information on psychoactive drugs to assess the need for their international control under the Single Convention on Narcotic Drugs, 1961, or the Convention on Psychotropic Substances, 1971. Evaluations are presented for fourteen substances, including four benzodiazepines, nine designer drugs (analogues of fentanyl, tenamfetamine and aminorex), and dronabinol. Recommendations are based on a review of pharmacological and epidemiological data together with evidence indicating the potential of serious abuse-related social and health problems. For each drug, a summary of effects on the central nervous system, dependence potential, likelihood of abuse, and therapeutic usefulness is followed by the committee's recommendations on scheduling under the international treaties. Proposals include the recommended scheduling of the benzodiazepine midazolam and the rescheduling, to provide for less stringent control, of dronabinol, which may be useful as an antiemetic adjunct to cancer chemotherapy. The committee also recommended that all nine designer drugs be subject to international control. The report concludes with general recommendations concerning specifications for the types of information required to facilitate decision-making on the international control of psychoactive substances.
eng fre rus spa.
WHODOC
9241207876
Substance-related disorders.
Substance abuse.
Drug and narcotic control.
Benzodiazepines.
Designer drugs.
Tetrahydrocannabinol.
WM 270
Records the recommendations of a WHO expert committee responsible for reviewing information on psychoactive drugs to assess the need for their international control under the Single Convention on Narcotic Drugs, 1961, or the Convention on Psychotropic Substances, 1971. Evaluations are presented for fourteen substances, including four benzodiazepines, nine designer drugs (analogues of fentanyl, tenamfetamine and aminorex), and dronabinol. Recommendations are based on a review of pharmacological and epidemiological data together with evidence indicating the potential of serious abuse-related social and health problems. For each drug, a summary of effects on the central nervous system, dependence potential, likelihood of abuse, and therapeutic usefulness is followed by the committee's recommendations on scheduling under the international treaties. Proposals include the recommended scheduling of the benzodiazepine midazolam and the rescheduling, to provide for less stringent control, of dronabinol, which may be useful as an antiemetic adjunct to cancer chemotherapy. The committee also recommended that all nine designer drugs be subject to international control. The report concludes with general recommendations concerning specifications for the types of information required to facilitate decision-making on the international control of psychoactive substances.
eng fre rus spa.
WHODOC
9241207876
Substance-related disorders.
Substance abuse.
Drug and narcotic control.
Benzodiazepines.
Designer drugs.
Tetrahydrocannabinol.
WM 270